These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

285 related articles for article (PubMed ID: 28320608)

  • 1. Antithrombotic agents for secondary prevention after acute coronary syndromes: A systematic review and network meta-analysis.
    Fanaroff AC; Hasselblad V; Roe MT; Bhatt DL; James SK; Steg PG; Gibson CM; Ohman EM
    Int J Cardiol; 2017 Aug; 241():87-96. PubMed ID: 28320608
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect and safety of antithrombotic therapies for secondary prevention after acute coronary syndrome: a network meta-analysis.
    Mo F; Li J; Yan Y; Wu W; Lai S
    Drug Des Devel Ther; 2018; 12():3583-3594. PubMed ID: 30498334
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and safety of antithrombotic regimens after coronary intervention in patients on oral anticoagulation: Traditional and Bayesian meta-analysis of clinical trials.
    Liu J; Fan M; Zhao J; Zhao B; Zhang C; Liu C; Dong Y
    Int J Cardiol; 2016 Feb; 205():89-96. PubMed ID: 26724753
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and Safety of Long-Term Antithrombotic Strategies in Patients With Chronic Coronary Syndrome: A Network Meta-analysis of Randomized Controlled Trials.
    Zhu H; Xu X; Fang X; Ying F; Song L; Gao B; Tong G; Zhou L; Chen T; Huang J
    J Am Heart Assoc; 2021 Mar; 10(6):e019184. PubMed ID: 33682435
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antithrombotic therapy in the early phase of non-ST-elevation acute coronary syndromes: a systematic review and meta-analysis.
    Galli M; Andreotti F; D'Amario D; Vergallo R; Vescovo GM; Giraldi L; Migliaro S; Ameri P; Porto I; Crea F
    Eur Heart J Cardiovasc Pharmacother; 2020 Jan; 6(1):43-56. PubMed ID: 31350546
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prophylactic Efficacy and Safety of Antithrombotic Regimens in Patients with Stable Atherosclerotic Cardiovascular Disease (S-ASCVD): A Bayesian Network Meta-Regression Analysis.
    Zheng N; Zhong J; Chen X; Su J; Liu C; Jiang L
    Am J Cardiovasc Drugs; 2023 May; 23(3):257-267. PubMed ID: 36867384
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Oral antithrombotic therapy in atrial fibrillation associated with acute or chronic coronary artery disease.
    Cairns JA; McMurtry MS
    Can J Cardiol; 2013 Jul; 29(7 Suppl):S60-70. PubMed ID: 23790600
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bleeding and ischaemic outcomes in patients treated with dual or triple antithrombotic therapy: systematic review and meta-analysis.
    Haller PM; Sulzgruber P; Kaufmann C; Geelhoed B; Tamargo J; Wassmann S; Schnabel RB; Westermann D; Huber K; Niessner A; Gremmel T
    Eur Heart J Cardiovasc Pharmacother; 2019 Oct; 5(4):226-236. PubMed ID: 31198930
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Within and beyond 12-month efficacy and safety of antithrombotic strategies in patients with established coronary artery disease: two companion network meta-analyses of the 2022 joint clinical consensus statement of the European Association of Percutaneous Cardiovascular Interventions (EAPCI), European Association for Acute CardioVascular Care (ACVC), and European Association of Preventive Cardiology (EAPC).
    Navarese EP; Landi A; Oliva A; Piccolo R; Aboyans V; Angiolillo D; Atar D; Capodanno D; Fox KAA; Halvorsen S; James S; Jüni P; Kunadian V; Leonardi S; Mehran R; Montalescot G; Niebauer J; Price S; Storey RF; Völler H; Vranckx P; Windecker S; Valgimigli M
    Eur Heart J Cardiovasc Pharmacother; 2023 Apr; 9(3):271-290. PubMed ID: 36869784
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison efficacy and safety of different antiplatelet or anticoagulation drugs in chronic coronary syndromes patients: A Bayesian network meta-analysis.
    Liu C; Ma L
    Medicine (Baltimore); 2023 Dec; 102(48):e36429. PubMed ID: 38050293
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinically significant bleeding with low-dose rivaroxaban versus aspirin, in addition to P2Y12 inhibition, in acute coronary syndromes (GEMINI-ACS-1): a double-blind, multicentre, randomised trial.
    Ohman EM; Roe MT; Steg PG; James SK; Povsic TJ; White J; Rockhold F; Plotnikov A; Mundl H; Strony J; Sun X; Husted S; Tendera M; Montalescot G; Bahit MC; Ardissino D; Bueno H; Claeys MJ; Nicolau JC; Cornel JH; Goto S; Kiss RG; Güray Ü; Park DW; Bode C; Welsh RC; Gibson CM
    Lancet; 2017 May; 389(10081):1799-1808. PubMed ID: 28325638
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The role of triple antithrombotic therapy in patients with atrial fibrillation undergoing percutaneous coronary intervention.
    Fanaroff AC; Lopes RD
    Prog Cardiovasc Dis; 2021; 69():11-17. PubMed ID: 34883097
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antiplatelet agents and anticoagulants for hypertension.
    Shantsila E; Kozieł-Siołkowska M; Lip GY
    Cochrane Database Syst Rev; 2022 Jul; 7():CD003186. PubMed ID: 35900898
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Secondary Prevention with Antithrombotic Therapies in Stable Ischemic Heart Disease Patients: a Review.
    Shanker A; Bhupathi V
    Curr Cardiol Rep; 2019 May; 21(7):56. PubMed ID: 31104152
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Is there a Role for Oral Triple Therapy in Patients with Acute Coronary Syndromes Without Atrial Fibrillation?
    Spinthakis N; Farag M; Akhtar Z; Gorog DA
    Curr Vasc Pharmacol; 2018; 16(5):427-436. PubMed ID: 29345587
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antithrombotic therapy for secondary prevention in patients with stroke or transient ischemic attack: A multiple treatment network meta-analysis of randomized controlled trials.
    Tornyos D; Komócsi A; Bálint A; Kupó P; El Abdallaoui OEA; Szapáry L; Szapáry LB
    PLoS One; 2022; 17(8):e0273103. PubMed ID: 35976963
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Role of novel and emerging oral anticoagulants for secondary prevention of acute coronary syndromes.
    Ganetsky VS; Hadley DE; Thomas TF
    Pharmacotherapy; 2014 Jun; 34(6):590-604. PubMed ID: 24338703
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety and Efficacy of Ticagrelor Monotherapy in Patients With Acute Coronary Syndromes Undergoing Percutaneous Coronary Intervention: An Individual Patient Data Meta-Analysis of TWILIGHT and TICO Randomized Trials.
    Baber U; Jang Y; Oliva A; Cao D; Vogel B; Dangas G; Sartori S; Spirito A; Smith KF; Branca M; Collier T; Pocock S; Valgimigli M; Kim BK; Hong MK; Mehran R
    Circulation; 2024 Feb; 149(8):574-584. PubMed ID: 37870970
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rivaroxaban 2.5 mg. No justification for using this anticoagulant after an acute coronary syndrome.
    Prescrire Int; 2014 Oct; 23(153):229-32. PubMed ID: 25964962
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Secondary prevention of antithrombotic therapy in patients with stable cardiovascular disease at high ischemic risk: A network meta-analysis of randomized controlled trials.
    Zhu H; Xu X; Wang H; Chen Q; Fang X; Zheng J; Gao B; Tong G; Zhou L; Chen T; Huang J
    Front Cardiovasc Med; 2022; 9():1040473. PubMed ID: 36698936
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.